Global nephroblastoma treatment market is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030).
Figure 1.Global Nephroblastoma Treatment Market Share (%), by Type, 2022
Increasing approvals from regulatory bodies to key players for nephroblastoma treatment in market are expected to drive growth of the nephroblastoma treatment market.
Key players in market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, in May 2022, Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial, which would have a starting dose of 1 mg/kg for the treatment of wilms’ tumor 1 (WT1)-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers.
Figure 2.Global Nephroblastoma Treatment Market Share (%), by Distribution Channel, 2022
Rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth during the forecast period.
Key players in market are focused on carrying out research and development activities for the development of drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, the Children's Oncology Group, a clinical trials group supported by the National Cancer Institute, is currently studying the effect of combination chemotherapy and surgery in treating young patients with wilms tumor. As of August 4, 2022, the study is currently in phase 3 of its clinical trial and the study is expected to be completed by November 2023.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients